This is great news!

Some initial questions:

1) Which SGLT2 inhibitors?

2) Will BETonMACE2 be all diabetics on rosuvastatin or atorvastatin again? My guess is yes.

3) How many total patients? How many CKD patients?

4) Will CKD patients be on SGLT2 inhibitors as well? We don't know how many CKD patients in BETonMACE were on SGLT2i.

5) What is the primary endpoint? What MACE category or MACE composite will be the focus? Some combination of CVD death, non-fatal MI and hospitalization for heart failure most likely.

6) What is the evidence of efficacy in NAFLD patients? This is the first we are hearing if this.

BDAZ